GACI First Investment Company Publication of Pricing Supplements (8626P)

TIDMSK19

RNS Number : 8626P

GACI First Investment Company

14 February 2023

GACI First Investment Company - Publication of Pricing Supplements

THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW

14 February 2023

The following pricing supplements (together, the "Pricing Supplements") are available for viewing:

The pricing supplement in relation to the issue of U.S.$ 1,750,000,000 4.750 per cent. Green Notes due 2030 by GACI First Investment Company (the "Issuer") under its Guaranteed Euro Medium Term Note Programme (the "Programme"). A copy of such pricing supplement can be viewed at:

http://www.rns-pdf.londonstockexchange.com/rns/8626P_1-2023-2-14.pdf

The pricing supplement in relation to the issue of U.S.$ 2,000,000,000 4.875 per cent. Green Notes due 2035 by the Issuer under the Programme. A copy of such pricing supplement can be viewed at:

http://www.rns-pdf.londonstockexchange.com/rns/8626P_2-2023-2-14.pdf

The pricing supplement in relation to the issue of U.S.$ 1,750,000,000 5.125 per cent. Green Notes due 2053 by the Issuer under the Programme. A copy of such pricing supplement can be viewed at:

http://www.rns-pdf.londonstockexchange.com/rns/8626P_3-2023-2-14.pdf

For further information, please contact: [e-mail]

DISCLAIMER - INTENDED ADDRESSEES

The Pricing Supplements must be read in conjunction with the offering circular dated 27 September 2022 in respect of the Programme as supplemented by the supplemental offering circular dated 7 February 2023 (together, the "Offering Circular").

Please note that the information contained in the Pricing Supplements and the Offering Circular may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Pricing Supplements and/or Offering Circular) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Pricing Supplements and/or Offering Circular is not addressed. Prior to relying on the information contained in the Offering Circular you must ascertain from the Pricing Supplements and Offering Circular whether or not you are part of the intended addressees of the information contained therein.

The Pricing Supplements do not constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction. The securities referred to in the Pricing Supplements have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act, and the rules and regulations thereunder. The Issuer does not intend to register the securities referred to in the Pricing Supplements in the United States or to conduct a public offering of the securities referred to in the Pricing Supplements in the United States or elsewhere.

Your right to access this service is conditional upon complying with the above requirement.

No offer or invitation to acquire any securities is being made pursuant to this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PFTFIFETFRISLIV

(END) Dow Jones Newswires

February 14, 2023 04:12 ET (09:12 GMT)